Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside
Replimune shares jumped 99% to $8.94 on Oct. 20, 2025, after the FDA accepted its resubmitted BLA for lead cancer therapy RP1 plus nivolumab, setting a PDUFA decision date for April 10, 2026. New trial data showed a 44% response rate in acral melanoma. The stock’s rebound follows a 73% plunge in July after an FDA rejection. Market cap stands near $698 million.
